Mesoblast limited (NASDAQ:MESO) Expected to Announce Quarterly Sales of $13.43 Million

Brokerages expect Mesoblast limited (NASDAQ:MESO) to announce $13.43 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Mesoblast’s earnings, with the lowest sales estimate coming in at $2.00 million and the highest estimate coming in at $24.87 million. Mesoblast reported sales of $1.97 million in the same quarter last year, which indicates a positive year over year growth rate of 581.7%. The company is scheduled to announce its next quarterly earnings results on Thursday, September 3rd.

According to Zacks, analysts expect that Mesoblast will report full-year sales of $39.87 million for the current fiscal year, with estimates ranging from $19.90 million to $61.24 million. For the next financial year, analysts anticipate that the company will post sales of $201.50 million, with estimates ranging from $37.00 million to $518.99 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Mesoblast.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings results on Wednesday, May 27th. The company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). The business had revenue of $12.20 million for the quarter, compared to the consensus estimate of $9.38 million. Mesoblast had a negative return on equity of 13.59% and a negative net margin of 197.65%.

Several research firms have weighed in on MESO. ValuEngine upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. LADENBURG THALM/SH SH upped their target price on Mesoblast from $13.00 to $15.25 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Zacks Investment Research downgraded Mesoblast from a “buy” rating to a “hold” rating in a research note on Wednesday, June 3rd. TheStreet upgraded Mesoblast from a “d+” rating to a “c-” rating in a research note on Friday, May 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $21.00 target price (up previously from $14.00) on shares of Mesoblast in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Mesoblast currently has a consensus rating of “Buy” and a consensus price target of $14.91.

Mesoblast stock traded down $0.35 during trading hours on Monday, hitting $11.21. 261,337 shares of the stock traded hands, compared to its average volume of 699,581. The company has a debt-to-equity ratio of 0.13, a current ratio of 0.90 and a quick ratio of 0.90. The firm’s 50 day moving average price is $12.55 and its 200-day moving average price is $8.89. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -17.13 and a beta of 3.53. Mesoblast has a 1 year low of $3.12 and a 1 year high of $20.57.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cetera Advisor Networks LLC acquired a new position in Mesoblast in the 1st quarter worth about $44,000. Ingalls & Snyder LLC acquired a new position in Mesoblast in the 1st quarter worth about $53,000. Aperio Group LLC acquired a new position in Mesoblast in the 1st quarter worth about $81,000. Wilbanks Smith & Thomas Asset Management LLC raised its holdings in Mesoblast by 6.0% in the 4th quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 25,025 shares of the company’s stock worth $184,000 after purchasing an additional 1,425 shares during the period. Finally, Morgan Stanley raised its holdings in Mesoblast by 93.4% in the 1st quarter. Morgan Stanley now owns 74,069 shares of the company’s stock worth $324,000 after purchasing an additional 35,777 shares during the period. 2.12% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Recommended Story: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.